Early Approval for Abbott AIDS Medicine

Article

(ABBOTT PARK, ILL)The Food and Drug Administration (FDA) has granted an early approval of the Abbott Laboratories' AIDS drug Kaletra, a form of protease inhibitor medication that has shown considerable promise in bringing the virus down to undetectable levels. Abbott applied for FDA approval on June 1, 2000 and was not expecting results until later this fall.

Kaletra is a mixture of two drugs, the main one generically called lopinavir and previously called ABT-378 in Abbott clinical labs, the other is ritonavir, already on the market as an AIDS drug under the brand name Norvir. For more information visit www.fda.gov.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
COVID-19 infection (Adobe Stock327378972 by rost9)
Swarm of Mosquitoes on Green Background Disease Carriers Insect Infestation  (Adobe Stock 1609688034 by Amith)
Structural detail of Hepatitis B virus on blue-green background. 3D illustration (Adobe Stock 239268660 by Destina)
© 2025 MJH Life Sciences

All rights reserved.